Carolina Frizzo-Ramos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carolina Frizzo-Ramos has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Iwan Anton Burgener
Clinical Unit of Small Animals Internal Medicine, Department for Companion Animals and Horses, University of Veterinary Medicine Vienna, 1210 Vienna, Austria
2 shared publications - Nicole Luckschander-Zeller
Clinical Unit of Small Animals Internal Medicine, Department for Companion Animals and Horses, University of Veterinary Medicine Vienna, 1210 Vienna, Austria
2 shared publications - Pavlos G. Doulidis
Clinical Unit of Internal Medicine Small Animals, Department for Companion Animals and Horses, University of Veterinary Medicine, Vienna, Austria
2 shared publications - Barbara C. Ruetgen
Clinical Pathology, Department of Pathobiology, University of Veterinary Medicine Vienna, Vienna, Austria
1 shared publication - Franziska Roth-Walter
Department of Biological Sciences and Pathobiology, University of Veterinary Medicine Vienna, Vienna, Austria
1 shared publication Larissa J Prankch
Clinical Unit of Small Animal Internal Medicine, Department for Companion Animals and Horses, University of Veterinary Medicine , 1210 Vienna
1 shared publication
Latest Publications
- Open Access
- 1 September 2026
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 40 (5)
ClotPro viscoelastic testing in coagulation disorders in dogs: a retrospective analysis
Background: Viscoelastic testing provides whole-blood assessment of coagulation, but clinical data on the performance of the ClotPro in dogs with naturally occurring diseases are limited. Hypothesis/Objectives: To evaluate pathway coherence of ClotPro variables with routine coagulation tests and to explore disease-associated viscoelastic phenotypes, fibrinolysis, and hypercoagulability. Animals: Eighty-four client-owned dogs admitted to a university hospital. Methods: Retrospective cohort study. ClotPro variables (clotting time, amplitude at 10 min, maximum clot firmness, maximum lysis across extrinsic pathway test [EX], intrinsic pathway test [IN], fibrinogen test channel, aprotinin test [AP] channels) were compared with prothrombin time (PT), activated partial thromboplastin time (aPTT), platelet count (PLT), and D-dimer using Spearman correlation with Benjamini–Hochberg adjustment. Group differences were assessed with Kruskal–Wallis and Dunn’s post hoc. Hyperfibrinolysis (HF) was defined using paired EX–AP. A hypercoagulability index (HCI) and platelet/fibrin-adjusted residual firmness were derived. Results: PT correlated with clotting time in EX channel (ρ = 0.48, q = 0.002) and aPTT with clotting time in IN channel (ρ = 0.42, q = 0.007). PLT correlated with maximum clot firmness in EX channel (EX_MCF) (ρ = 0.50, q = 0.001). maximum clot firmness in FIB channel correlated with EX_MCF (ρ = 0.58, q < 0.001) and maximum clot firmness in IN channel (ρ = 0.47, q = 0.003). maximum lysis in EX channel (EX_ML) correlated inversely with EX_MCF (ρ = −0.35, q = 0.028). D-dimer correlated with EX_ML (ρ = 0.30, q = 0.049). Group-level distributions overlapped substantially. HF was infrequent among cases (33% in dogs with hepatopathy and 21% in dogs with hemorrhagic diarrhea). The HCI differed across diseases (P = .0002), whereas platelet/fibrin-adjusted residual firmness did not. Conclusions and clinical importance: ClotPro variables demonstrated pathway-specific coherence with routine coagulation testing and consistent fibrinolysis patterns. Disease states did not define discrete viscoelastic phenotypes, supporting case-level interpretation.
- 1 September 2026
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 40 (5)
Open AccessClotPro viscoelastic testing in coagulation disorders in dogs: a retrospective analysis
Background: Viscoelastic testing provides whole-blood assessment of coagulation, but clinical data on the performance of the ClotPro in dogs with naturally occurring diseases are limited. Hypothesis/Objectives: To evaluate pathway coherence of ClotPro variables with routine coagulation tests and to explore disease-associated viscoelastic phenotypes, fibrinolysis, and hypercoagulability. Animals: Eighty-four client-owned dogs admitted to a university hospital. Methods: Retrospective cohort study. ClotPro variables (clotting time, amplitude at 10 min, maximum clot firmness, maximum lysis across extrinsic pathway test [EX], intrinsic pathway test [IN], fibrinogen test channel, aprotinin test [AP] channels) were compared with prothrombin time (PT), activated partial thromboplastin time (aPTT), platelet count (PLT), and D-dimer using Spearman correlation with Benjamini–Hochberg adjustment. Group differences were assessed with Kruskal–Wallis and Dunn’s post hoc. Hyperfibrinolysis (HF) was defined using paired EX–AP. A hypercoagulability index (HCI) and platelet/fibrin-adjusted residual firmness were derived. Results: PT correlated with clotting time in EX channel (ρ = 0.48, q = 0.002) and aPTT with clotting time in IN channel (ρ = 0.42, q = 0.007). PLT correlated with maximum clot firmness in EX channel (EX_MCF) (ρ = 0.50, q = 0.001). maximum clot firmness in FIB channel correlated with EX_MCF (ρ = 0.58, q < 0.001) and maximum clot firmness in IN channel (ρ = 0.47, q = 0.003). maximum lysis in EX channel (EX_ML) correlated inversely with EX_MCF (ρ = −0.35, q = 0.028). D-dimer correlated with EX_ML (ρ = 0.30, q = 0.049). Group-level distributions overlapped substantially. HF was infrequent among cases (33% in dogs with hepatopathy and 21% in dogs with hemorrhagic diarrhea). The HCI differed across diseases (P = .0002), whereas platelet/fibrin-adjusted residual firmness did not. Conclusions and clinical importance: ClotPro variables demonstrated pathway-specific coherence with routine coagulation testing and consistent fibrinolysis patterns. Disease states did not define discrete viscoelastic phenotypes, supporting case-level interpretation.
- Open Access
- 8 July 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (7) , 997
Altered Iron Metabolism in Dogs with Naturally Occurring Cardiac Disease
Cardiac disease represents a major cause of morbidity and mortality in dogs. In human cardiology, iron deficiency is a highly prevalent and clinically relevant comorbidity, contributing to exercise intolerance, symptom burden, and impaired quality of life independently of anemia, while correction with intravenous iron improves function and reduces hospitalization. Iron metabolism in dogs remains poorly characterized and typically considered only in the context of anemia. This study investigated iron metabolism and its regulatory pathways in dogs with cardiac disease, assessing whether alterations in iron handling and availability consistent with an iron-restricted phenotype are present. Hematologic indices, serum iron, total and unsaturated iron-binding capacity (TIBC, UIBC), ferritin, hepcidin, ceruloplasmin, C-reactive protein, and albumin were evaluated in 61 dogs comprising healthy controls, and dogs either with compensated cardiac disease (CCD group) or presenting acute decompensated congestive heart failure (ADCHF group). Dogs with cardiac disease exhibited evidence of systemic inflammation, reduced hematocrit, increased red blood cell distribution width, and decreased circulating iron. Both cardiac groups showed reduced TIBC and UIBC, suggesting decreased transferrin availability and reduced iron transport capacity, whereas ferritin concentrations did not differ between groups. Hepcidin concentrations were lower in CCD and not increased in ADCHF patients, suggesting complex and non-uniform regulation of iron homeostasis rather than a classic hepcidin-driven inflammatory pattern. In dogs with ADCHF, iron-binding capacity was independently associated with indices of cardiac remodeling, and additional correlation between inflammatory markers and iron-related parameters supported an interaction between inflammation, iron handling, and disease severity.
- 8 July 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (7) , 997
Open AccessAltered Iron Metabolism in Dogs with Naturally Occurring Cardiac Disease
Cardiac disease represents a major cause of morbidity and mortality in dogs. In human cardiology, iron deficiency is a highly prevalent and clinically relevant comorbidity, contributing to exercise intolerance, symptom burden, and impaired quality of life independently of anemia, while correction with intravenous iron improves function and reduces hospitalization. Iron metabolism in dogs remains poorly characterized and typically considered only in the context of anemia. This study investigated iron metabolism and its regulatory pathways in dogs with cardiac disease, assessing whether alterations in iron handling and availability consistent with an iron-restricted phenotype are present. Hematologic indices, serum iron, total and unsaturated iron-binding capacity (TIBC, UIBC), ferritin, hepcidin, ceruloplasmin, C-reactive protein, and albumin were evaluated in 61 dogs comprising healthy controls, and dogs either with compensated cardiac disease (CCD group) or presenting acute decompensated congestive heart failure (ADCHF group). Dogs with cardiac disease exhibited evidence of systemic inflammation, reduced hematocrit, increased red blood cell distribution width, and decreased circulating iron. Both cardiac groups showed reduced TIBC and UIBC, suggesting decreased transferrin availability and reduced iron transport capacity, whereas ferritin concentrations did not differ between groups. Hepcidin concentrations were lower in CCD and not increased in ADCHF patients, suggesting complex and non-uniform regulation of iron homeostasis rather than a classic hepcidin-driven inflammatory pattern. In dogs with ADCHF, iron-binding capacity was independently associated with indices of cardiac remodeling, and additional correlation between inflammatory markers and iron-related parameters supported an interaction between inflammation, iron handling, and disease severity.